| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diphtheria | D004165 | 2 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Dermatomycoses | D003881 | 17 associated lipids |
| Drug Eruptions | D003875 | 30 associated lipids |
| Dermatitis, Exfoliative | D003873 | 10 associated lipids |
| Cysts | D003560 | 4 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Cross Infection | D003428 | 9 associated lipids |
| Conjunctivitis, Bacterial | D003234 | 3 associated lipids |
| Conjunctival Neoplasms | D003230 | 3 associated lipids |
| Confusion | D003221 | 4 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Chromoblastomycosis | D002862 | 2 associated lipids |
| Chlamydia Infections | D002690 | 7 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Bronchitis | D001991 | 6 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kajihara Y et al. | Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. | 2017 | Scand. J. Gastroenterol. | pmid:27806639 |
| Yan J et al. | Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital. | 2017 | Eur Arch Otorhinolaryngol | pmid:28508178 |
| Shaulov A et al. | Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. | 2017 | Am. J. Hematol. | pmid:27804150 |
| DaCosta A et al. | Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. | 2017 | J. Cyst. Fibros. | pmid:28495380 |
| Malfertheiner P et al. | Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. | 2017 | Gut | pmid:27707777 |
| Sharifi R et al. | Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. | 2017 | Lipids | pmid:28493185 |
| Reddy AB and Reddy ND | Development of Multiple-Unit Floating Drug Delivery System of Clarithromycin: Formulation, in vitro Dissolution by Modified Dissolution Apparatus, in vivo Radiographic Studies in Human Volunteers. | 2017 | Drug Res (Stuttg) | pmid:28449156 |
| Aktas AH and Saridag AM | Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. | 2017 | J Chromatogr Sci | pmid:28449104 |
| Itskoviz D et al. | Smoking increases the likelihood of Helicobacter pylori treatment failure. | 2017 | Dig Liver Dis | pmid:28427781 |
| Koštrun S et al. | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. | 2017 | Eur J Med Chem | pmid:28410508 |
| Giguère S et al. | Antimicrobial Resistance in . | 2017 | Microbiol Spectr | pmid:29052538 |
| Berni E et al. | Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. | 2017 | BMJ Open | pmid:28115334 |
| Costa S et al. | Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. | 2017 | Eur J Gastroenterol Hepatol | pmid:28877088 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Takahashi C et al. | Morphological study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infection disease. | 2017 | Med Mol Morphol | pmid:27119723 |
| Ruiter R et al. | Helicobacter pylori resistance in the Netherlands: a growing problem? | 2017 | Neth J Med | pmid:29219812 |
| Oh ES et al. | Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. | 2017 | J Clin Pharm Ther | pmid:28806472 |
| Kuo YT et al. | Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. | 2017 | Lancet Gastroenterol Hepatol | pmid:28781119 |
| Ramas M et al. | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. | 2017 | Gastroenterol Hepatol | pmid:28780968 |
| Painsi C and Lange-Asschenfeldt B | Image Gallery: Pink papules within a tattoo linked to Mycobacterium chelonae infection. | 2017 | Br. J. Dermatol. | pmid:28731256 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Kishida D et al. | Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus. | 2017 | Intern. Med. | pmid:28502947 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Sharman MJ et al. | Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. | 2017 | Vet. Immunol. Immunopathol. | pmid:28494926 |
| O'Brien CR et al. | Feline leprosy due to Candidatus 'Mycobacterium tarwinense':Further clinical and molecular characterisation of 15 previously reported cases and an additional 27 cases | 2017 | J. Feline Med. Surg. | pmid:28438086 |
| Tan B et al. | Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. | 2017 | PLoS ONE | pmid:28407007 |
| Olesen JS et al. | Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. | 2017 | BMJ Case Rep | pmid:28137898 |
| Chang JY et al. | Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. | 2017 | BMC Gastroenterol | pmid:28109257 |
| Sasaoka Y et al. | Neonatal apnea with Chlamydia pneumoniae infection. | 2017 | Pediatr Int | pmid:28102626 |
| Lapa GB et al. | Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin. | 2017 | J Enzyme Inhib Med Chem | pmid:28097898 |
| Losurdo G et al. | Role of concomitant therapy for eradication: A technical note. | 2016 | World J. Gastroenterol. | pmid:27784977 |
| Zycinska K et al. | Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. | 2016 | Adv. Exp. Med. Biol. | pmid:27620311 |
| Hirata Y et al. | Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. | 2016 | Int. J. Infect. Dis. | pmid:27590563 |
| Zhou L et al. | Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. | 2016 | Helicobacter | pmid:26104022 |
| Couture G et al. | [Second case of serum sickness-like reaction to claritrhomycin]. | 2016 | Presse Med | pmid:27542759 |
| Bugli F et al. | In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. | 2016 | Biotechnol. Prog. | pmid:27535356 |
| Shichijo S et al. | Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. | 2016 | J Dig Dis | pmid:27534444 |
| Lotfipour F et al. | Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori. | 2016 | Drug Res (Stuttg) | pmid:25919643 |
| Miyaki A et al. | An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. | 2016 | Minerva Gastroenterol Dietol | pmid:27304198 |
| Akram FE et al. | A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). | 2016 | Ann. Clin. Microbiol. Antimicrob. | pmid:27530257 |
| Fallone CA et al. | The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. | 2016 | Gastroenterology | pmid:27102658 |
| Bilgilier C et al. | Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. | 2016 | Ann. Hematol. | pmid:27091350 |
| Root AA et al. | Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. | 2016 | Br J Clin Pharmacol | pmid:27090996 |
| Kazama I et al. | Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. | 2016 | Chemotherapy | pmid:27088971 |
| Guirao-Arrabal E et al. | Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. | 2016 | Rev Esp Quimioter | pmid:26888341 |
| Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
| Mukai S et al. | Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. | 2016 | Int. J. Oncol. | pmid:26718641 |
| Hassan ST et al. | In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. | 2016 | Pharm Biol | pmid:26731378 |
| Çağan-Appak Y et al. | Clarithromycin resistance and 23S rRNA gene point mutations of Helicobacter pylori infection in children. | 2016 | Turk. J. Pediatr. | pmid:28276208 |
| Oh B et al. | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. | 2016 | Helicobacter | pmid:26395781 |